Paclitaxel and carboplatin combination chemotherapy has remained the standard of care in
the frontline therapy of advanced epithelial ovarian carcinoma during the last decade …

The standard first-line chemotherapy in EOC is based on the doublet carboplatin plus
paclitaxel. It may be possible to improve the efficacy of treatment by means of a more …

Ovarian cancer is still the fourth cause of death by cancer among women and the most fatal
among gynecological tumors. The purpose of this symposium is, year after year, to report …

The standard initial management of epithelial ovarian cancer consists of surgical staging,
operative tumour debulking including total abdominal hysterectomy and bilateral salpingo …

Objective As a result of relevant achievements in the field of translational research, several
active drugs and multiple biological targets are available in ovarian cancer (OC). In this …

AIMS: Epithelial ovarian cancer is responsible for 4% of all cancer deaths in women, and the
five-year overall survival of patients with advanced disease is 30–40%. Treatment currently …

Financial Disclosure Ernst Lengyel disclosed that money was paid to his institution from
AbbVie (funding preclinical studies), NCI (RO1 grants), and the Ovarian Cancer Research …

Ovarian cancer is the most lethal of the gynaecological cancers, affecting approximately 1 in
75 women in the developed world. In most cases (> 75%), the disease is disseminated …

Purpose Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death
in the United States. Most patients will ultimately fail platinum-based chemotherapy and …

Background Suppression of neoangiogenesis and pegylated liposomal doxorubicin (PLD)
each contribute to the management of platinum-resistant/refractory ovarian cancer. The aim …